News

Richard Castledine talks to Pharmaceutical Technology about moving off the critical path and streamlining strategies for drug substance synthesis and manufacturing

Helen Baker, Director, Pharmaceutical Sci­ences at Quotient Sciences has recently been featured in Drug Development & Delivery's Special Feature: "Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product"

Mark Egerton, CEO of Quotient Sciences was recently asked to contribute to a piece with Pharma's Almanac, entitled 'What’s the key to being a leader in the industry?'

Roundtable Interview with Paul Quigley, Principal Research Fellow, Drug Substance,& John McDermott, Executive Drug Development Consultant. Low-volume drugs, such as orphan drugs, present challenges in achieving favorable production economics and in managing the projects themselves. A roundtable of CDMOs provides perspectives on those challenges and best practices to resolve them.

Mark Egerton, CEO of Quotient Sciences, has been featured in and article in Global Business Reports: "Keeping Up With Demands: CDMOs diversify their capabilities to meet their clients’ complex requirements."

Nand Singh, Medical Director at Quotient Sciences, contributes to a recent bial study paper in the British Journal of Clinical Pharmacology. This paper documents the study - absorption, metabolism and excretion of opicapone (2,5-dichloro-3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor investigations.